10-Year Outcomes Similar for H-IMRT, C-IMRT in Prostate Cancer

MONDAY, March 23, 2020 -- For men with intermediate- and high-risk prostate adenocarcinoma, 10-year outcomes are similar with conventionally fractionated intensity-modulated radiation therapy (C-IMRT) or moderate hypofractionated IMRT (H-IMRT),...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news

Related Links:

Authors: Konat-Bąska K, Chicheł A, Staszek-Szewczyk U, Maciejczyk A, Matkowski R Abstract Purpose: Prostate and colorectal cancers are the first and the third most popular malignancies in male population, in which some patients may develop these tumors metachronously or synchronously. At present, there are no standard recommendations, and oncologists need to provide an optimal management for two different cancers with an acceptable risk of possible treatment of adverse effects. Material and methods: This case report presents the treatment of a 61-year-old patient suffering from synchronous prostate and rectal...
Source: Journal of Contemporary Brachytherapy - Category: Cancer & Oncology Tags: J Contemp Brachytherapy Source Type: research
CONCLUSION: H-IMRT failed to demonstrate superiority compared with C-IMRT in long-term disease outcomes. PMID: 32119599 [PubMed - as supplied by publisher]
Source: Clinical Prostate Cancer - Category: Cancer & Oncology Authors: Tags: J Clin Oncol Source Type: research
Abstract AIM: To report toxicity and quality of life (QOL) outcomes from a randomised trial of prostate only versus whole pelvic radiotherapy in high risk, node negative prostate cancer. MATERIALS/METHODS: Patients with localised prostate adenocarcinoma and nodal involvement risk > 20%, were randomised to prostate only (PORT, 68 Gy/25# to prostate) and whole pelvis (WPRT, 68 Gy/25# to prostate and 50 Gy/25# to pelvis) arms with stratification for TURP, Gleason score, baseline PSA, and type of androgen deprivation therapy (ADT). Image guided intensity modulated radiotherapy (IG-IMRT...
Source: Radiotherapy and Oncology : journal of the European Society for Therapeutic Radiology and Oncology - Category: Radiology Authors: Tags: Radiother Oncol Source Type: research
Conditions:   Metastatic Prostate Adenocarcinoma;   Prostate Adenocarcinoma;   Recurrent Prostate Carcinoma;   Stage IV Prostate Cancer AJCC v8;   Stage IVA Prostate Cancer AJCC v8;   Stage IVB Prostate Cancer AJCC v8 Interventions:   Radiation: Intensity-Modulated Radiation Therapy;   Radiation: Proton Beam Radiation Therapy;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration Sponsors:   Mayo...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Three-dimensional conformal radiation therapy, intensity-modulated radiotherapy (IMRT), and volumetric-modulated arc radiotherapy (VMAT) are more effective curative treatment options for patients with localized adenocarcinoma of the prostate, compared with surgery [1 –2]. Gastrointestinal toxicity is the major treatment-related side effect in prostate cancer radiotherapy. The rates of acute and chronic grade (≥2) rectal toxicity increase by dose – increasing from 3 and 5%, to 20 and 21%, respectively [3–5].
Source: Physica Medica: European Journal of Medical Physics - Category: General Medicine Authors: Tags: Technical note Source Type: research
ConclusionCombining radiation dose parameters with microRNA expression in PBLs may be useful for predicting acute gastrointestinal toxicity of radiation therapy, thus contributing to personalized treatment of prostate cancer.
Source: Japanese Journal of Clinical Oncology - Category: Cancer & Oncology Source Type: research
Condition:   Stage II Prostate Adenocarcinoma Interventions:   Radiation: Intensity-Modulated Radiation Therapy (IMRT);   Radiation: Stereotactic Body Radiation Therapy (SBRT) Sponsors:   NRG Oncology;   National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Intensity-Modulated Radiation Therapy | Pharmaceuticals | Prostate Cancer | Radiation Therapy